The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma : Molecular diagnosis and therapy of cancer. Part 2JÄNNE, Pasi A.Annals of medicine (Helsinki). 2003, Vol 35, Num 7, pp 450-457, issn 0785-3890, 8 p.Article

New Strategies for Treatment of ALK-Rearranged Non―Small Cell Lung CancersSASAKI, Takaaki; JÄNNE, Pasi A.Clinical cancer research (Print). 2011, Vol 17, Num 23, pp 7213-7218, issn 1078-0432, 6 p.Article

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in CancerTOSCHI, Luca; JÄNNE, Pasi A.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 5941-5946, issn 1078-0432, 6 p.Article

Crizotinib for ALK-Rearranged Non―Small Cell Lung Cancer: A New Targeted Therapy for a New TargetGANDHI, Leena; JÄNNE, Pasi A.Clinical cancer research (Print). 2012, Vol 18, Num 14, pp 3737-3742, issn 1078-0432, 6 p.Article

Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant CancersOKUMURA, Shunsuke; JÄNNE, Pasi A.Clinical cancer research (Print). 2014, Vol 20, Num 16, pp 4193-4199, issn 1078-0432, 7 p.Article

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumoursJÄNNE, Pasi A.Lung cancer. 2008, Vol 60, issn 0169-5002, S3-S9, SUP2Conference Paper

ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung AdenocarcinomaJANNE, Pasi A; MEYERSON, Matthew.Journal of clinical oncology. 2012, Vol 30, Num 8, pp 878-879, issn 0732-183X, 2 p.Article

Biotinylated Probe Isolation of Targeted Gene Region Improves Detection of T790M Epidermal Growth Factor Receptor Mutation via Peptide Nucleic Acid―Enriched Real-Time PCRJIN LI; JÄNNE, Pasi A; MIKE MAKRIGIORGOS', G et al.Clinical chemistry (Baltimore, Md.). 2011, Vol 57, Num 5, pp 770-773, issn 0009-9147, 4 p.Article

Basic treatment considerations using chemotherapy for patients with small cell lung cancerJOHNSON, Bruce E; JÄNNE, Pasi A.Hematology/oncology clinics of North America. 2004, Vol 18, Num 2, pp v-vi, issn 0889-8588, 16 p.Article

Novel agents in the treatment of lung cancerLYNCH, Thomas J; JÄNNE, Pasi A; GURUBHAGAVATULA, Sarada et al.Clinical cancer research. 2004, Vol 10, Num 12, issn 1078-0432, 92 p., 2Conference Proceedings

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populationsJÄNNE, Pasi A.Seminars in oncology. 2005, Vol 32, Num 6, pp 9-15, issn 0093-7754, 7 p., SUP10Conference Paper

Epidermal growth factor receptor mutations in patients with non-small cell lung cancerJOHNSON, Bruce E; JÄNNE, Pasi A.Cancer research (Baltimore). 2005, Vol 65, Num 17, pp 7525-7529, issn 0008-5472, 5 p.Article

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerHAMMERMAN, Peter S; JÄNNE, Pasi A; JOHNSON, Bruce E et al.Clinical cancer research (Print). 2009, Vol 15, Num 24, pp 7502-7509, issn 1078-0432, 8 p.Article

Therapeutic targeting of multiple signaling pathways in malignant pleural mesotheliomaMUKOHARA, Toru; CIVIELLO, Gabriel; JOHNSON, Bruce E et al.Oncology. 2005, Vol 68, Num 4-6, pp 500-510, issn 0030-2414, 11 p.Article

The role of gefitinib in lung cancer treatmentGIACCONE, Giuseppe.Clinical cancer research. 2004, Vol 10, Num 12, pp 4233s-4237s, issn 1078-0432, 2Conference Paper

Cetuximab in advanced non-small cell lung cancerGOVINDAN, Ramaswamy.Clinical cancer research. 2004, Vol 10, Num 12, pp 4241s-4244s, issn 1078-0432, 2Conference Paper

Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCRJIN LI; LILIN WANG; JÄNNE, Pasi A et al.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 4, pp 748-756, issn 0009-9147, 9 p.Article

Management of Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors in Patients With Advanced Non-Small Cell Lung CancerSACHER, Adrian G; JANNE, Pasi A; OXNARD, Geoffrey R et al.Cancer. 2014, Vol 120, Num 15, pp 2289-2298, issn 0008-543X, 10 p.Article

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapyWIRTH, Lori J; CARTER, Mark R; JÄNNE, Pasi A et al.Lung cancer. 2004, Vol 44, Num 2, pp 213-220, issn 0169-5002, 8 p.Article

Cytotoxic chemotherapy in advanced Non-Small Cell Lung cancer: A review of standard treatment paradigmsSOCINSKI, Mark A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4210s-4214s, issn 1078-0432, 2Conference Paper

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignanciesROWINSKY, Eric K.Clinical cancer research. 2004, Vol 10, Num 12, pp 4220s-4226s, issn 1078-0432, 2Conference Paper

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesotheliomaJÄNNE, Pasi A; TAFFARO, Michele L; SALGIA, Ravi et al.Cancer research (Baltimore). 2002, Vol 62, Num 18, pp 5242-5247, issn 0008-5472, 6 p.Article

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Clinical trial design issues in the era of targeted therapiesSCHILLER, Joan H.Clinical cancer research. 2004, Vol 10, Num 12, pp 4281s-4282s, issn 1078-0432, 2Conference Paper

Cyclooxygenase as a target in lung cancerBROWN, Joanne R; DUBOIS, Raymond N.Clinical cancer research. 2004, Vol 10, Num 12, pp 4266s-4269s, issn 1078-0432, 2Conference Paper